Bg pattern

MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Mepivacaine B. Braun 20 mg/ml Solution for Injection

Mepivacaine Hydrochloride

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

Read the entire package leaflet carefully before starting to use this medication because it contains important information for you

  • Keep this package leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • If you experience side effects, consult your doctor, pharmacist, or nurse, even if they are not listed in this package leaflet. See section 4.

Contents of the Package Leaflet:

  1. What Mepivacaine B. Braun 20 mg/ml is and what it is used for
  2. What you need to know before using Mepivacaine B. Braun 20 mg/ml
  3. How to use Mepivacaine B. Braun 20 mg/ml
  4. Possible side effects
  5. Storage of Mepivacaine B. Braun 20 mg/ml
  6. Package Contents and Additional Information
Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

1. What Mepivacaine B. Braun 20 mg/ml is and what it is used for

Mepivacaine is a medication that belongs to the group of local anesthetics of the amide type and is indicated for epidural and caudal anesthesia, peripheral nerve blockade, nerve plexus blockade, and anesthesia for ophthalmic surgery.

Depending on the amount used, it will either completely stop the pain or cause partial loss of sensitivity.

It is used before surgery or various medical examinations to prevent or alleviate pain in the area of your body where the procedure will be performed.

2. What you need to know before using Mepivacaine B. Braun 20 mg/ml

Mepivacaine B. Braun 20 mg/ml should not be administered to you:

  • if you are allergic to mepivacaine hydrochloride or to any of the other components of this medication (listed in section 6).
  • if you are allergic to other local anesthetics, e.g., bupivacaine, lidocaine.
  • if you have severe blood coagulation disorders.
  • if you have degenerative nerve disease.
  • if you have serious heart conduction problems or other heart problems.
  • if you have uncontrolled epilepsy.
  • If you have increased intracranial pressure.

Warnings and Precautions

Consult your doctor or nurse before Mepivacaine B. Braun 20 mg/ml is administered to you:

  • if you have degenerative nerve disease.

  • The dose you will receive will be carefully controlled to avoid mepivacaine causing toxic reactions in your heart or nerves and brain.
  • You will be closely monitored while Mepivacaine B. Braun 20 mg/ml is administered to detect any complications that may affect heart function, blood circulation, or nervous and brain functions as soon as possible, and to provide any necessary treatment in case such complications occur.

Other Medications and Mepivacaine B. Braun 20 mg/ml

Tell your doctor if you are using, have recently used, or might use any other medication.

The administration of Mepivacaine B. Braun 20 mg/ml together with the following medications may make it necessary to modify the dose of any of them or interrupt treatment:

  • strong painkillers;
  • other local anesthetics;
  • certain medications used to treat heart rhythm disorders;
  • general anesthetics such as ether;
  • medications that cause vasoconstriction (reduction of blood vessel diameter);
  • heparin, anticoagulant medications (which prevent blood coagulation), non-steroidal anti-inflammatory drugs, and plasma substitutes (products used in case of blood loss). Your blood coagulation function will be carefully monitored if you are receiving any of these medications;
  • cytochrome PYP 1A2 inhibitors (such as ciprofloxacin, enoxacin, or fluvoxamine);
  • medications used to treat stomach and intestinal ulcers (such as cimetidine);
  • Propranolol.

Mepivacaine is generally not combined with other local anesthetics.

Use in Children and Elderly

Elderly patients require lower doses than young or middle-aged adults.

It should not be used in children and adolescents under 15 years of age.

Pregnancy, Breastfeeding, and Fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medication.

During pregnancy, Mepivacaine B. Braun 20 mg/ml will only be administered after careful consideration of the indications and if your doctor considers it absolutely necessary. Your doctor will take any possible precautions to avoid harm to you or your unborn child.

Mepivacaine is not a preferred drug for epidural anesthesia in obstetrics.

This medication will be administered during breastfeeding only if your doctor considers it necessary. If such administration is necessary, breastfeeding should be interrupted until 24 hours after the end of treatment.

Driving and Using Machines

Mepivacaine B. Braun 20 mg/ml may temporarily alter your ability to move, attention, and coordination. Your doctor will indicate if you can drive or use machines.

Mepivacaine B.Braun 20 mg/ml contains sodium

Ampoules of 5 ml:

This medication contains less than 23 mg of sodium (1 mmol) per 5 ml ampoule, which is essentially "sodium-free".

Ampoules of 10 ml:

This medication contains less than 23 mg of sodium (1 mmol) per 10 ml ampoule, which is essentially "sodium-free".

Ampoules of 20 ml:

This medication contains 40 mg of sodium (the main component of table salt/cooking salt) in each 20 ml ampoule. This is equivalent to 2% of the maximum recommended daily sodium intake for an adult.

3. How to Use Mepivacaine B. Braun 20 mg/ml

Mepivacaine B. Braun 20 mg/ml is administered via the epidural and perineural route for nerve conduction blockade and administration routes for peri and retrobulbar blocks in ophthalmic surgery.

It will be administered by healthcare personnel only, and your doctor will determine the most suitable dose for you. The smallest required dose should always be used to produce the desired anesthesia. The dosage must be adjusted individually according to the patient's age, weight, and specific case particulars.

In patients with liver, kidney, heart disease, poor general condition, and in elderly patients, special caution and careful dose adjustment are necessary.

Your doctor will ask you to talk to them while administering the medication to ensure you are conscious.

Your blood pressure may be measured from time to time.

If you are administered more Mepivacaine B. Braun 20 mg/ml than you should:

Overdose can cause signs and symptoms of intoxication. The severity of the signs and symptoms depends on the administered dose. The following may be observed:

  1. Central nervous system symptoms:

Mild intoxication:

Numbness and tingling in the mouth area, metallic taste, hearing and vision disturbances, yawning, anxiety, restlessness, shivering, muscle spasms, nausea, vomiting, disorientation.

Moderate intoxication:

Speech disorders, drowsiness, nausea, vomiting, dizziness, drowsiness, confusion, tremors, choreiform movements, convulsions, mydriasis, tachypnea.

Severe intoxication:

Vomiting (risk of asphyxia), sphincter paralysis, loss of muscle tone and reactivity, stupor, irregular breathing, respiratory paralysis, coma, death.

  1. Cardiovascular system symptoms

Mild intoxication:

Palpitations, hypertension, tachycardia, tachypnea.

Moderate intoxication:

Tachycardia, cardiac arrhythmias, hypoxia, pallor.

Severe intoxication:

Severe hypoxia and cyanosis, primary cardiac failure, hypotension, cardiac arrhythmias (bradycardia, atrial fibrillation, asystole).

In such cases, you will receive the necessary treatment first to normalize and stabilize your heart, circulation, and respiratory functions, and then to control convulsions and other severe nervous symptoms. This includes administering oxygen and additional medication, mainly to normalize heart function and circulation.

In case of overdose or accidental ingestion, consult your doctor, nurse, or pharmacist immediately or call the Toxicology Information Service, phone: 91 652 04 20, indicating the medication and the amount ingested.

4. Possible Side Effects

Like all medications, this medication can cause side effects, although not everyone will experience them.

Frequent(may affect up to 1 in 10 people):

  • Burning sensation, pinpricks, and tingling in the skin (paresthesia) and dizziness.
  • Slow and abnormal heart rate (bradycardia).
  • Hypotension.
  • Hypertension.
  • Nausea.
  • Vomiting.

Uncommon (may affect up to 1 in 100 people):

  • Dizziness (mild dizziness).
  • Tremors.
  • Central nervous system depression.
  • Loss of consciousness.
  • Convulsions (including epileptic seizures).
  • Speech disorders such as difficulty articulating sounds and words (dysarthria) and excessive talkativeness (logorrhea).
  • Visual impairment
  • Tinnitus (ringing in the ears).

Rare (may affect up to 1 in 1,000 people):

  • Anaphylactic/anaphylactoid reactions.
  • Allergic reactions.
  • Pain due to nerve injury (neuropathy).
  • Peripheral neural damage
  • Arachnoiditis.
  • Diplopia (paralysis of the eye muscles).
  • Cardiac arrest.
  • Angina pectoris.
  • Heart rhythm coordination problems (atrioventricular block).
  • Cardiac arrhythmia.
  • Breathing difficulties.

Frequency not known (frequency cannot be estimated from available data):

  • Euphoria.
  • Anxiety/nervousness.
  • Inability of the heart to contract effectively (myocardial depression)

Side Effects Due to Misuse

Extensive spinal anesthesia (total) can occur through accidental intrathecal injection during planned epidural anesthesia, as a result of using too large a volume or incorrect patient positioning (when non-isobaric solutions are used).

The first signs are restlessness and drowsiness, which can lead to loss of consciousness and respiratory arrest.

Reporting Side Effects

If you experience any side effects, consult your doctor or pharmacist, even if they are not listed in this package leaflet. You can also report them directly through the Spanish Medicines and Healthcare Products Agency's Pharmacovigilance System: www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of Mepivacaine B. Braun 20 mg/ml

Keep out of sight and reach of children.

No special storage conditions are required.

Do not use Mepivacaine B. Braun 20 mg/ml after the expiration date stated on the package (after EXP). The expiration date is the last day of the month indicated.

The contents of the ampoule should be used immediately after opening. Once opened, discard the unused portion of the solution. For single use only. Do not use this medication if you observe particles.

Medications should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the package and any unused medication. This will help protect the environment.

6. Package Contents and Additional Information

Composition of Mepivacaine B. Braun 20 mg/ml

Active Ingredient

Per 1 ml

Per 5 ml

Per 10 ml

Per 20 ml

Mepivacaine Hydrochloride

20 mg

100 mg

200 mg

400 mg

The other excipients are: sodium chloride, sodium hydroxide (for pH adjustment), and water for injectable preparations in sufficient quantity.

Appearance of the Product and Package Contents

Mepivacaine B. Braun 20 mg/ml is an injectable solution presented in 5, 10, and 20 ml polyethylene (Mini-Plasco) ampoules. It is presented in packages of 1 ampoule and 100 ampoules.

Not all formats may be marketed.

Marketing Authorization Holder and Manufacturer

  • Braun Medical, S.A.

Ctra. de Terrassa, 121

08191-Rubí (Barcelona)

Spain

Date of the Last Revision of this Package Leaflet: August 2020

Detailed and updated informationon this medication is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS):http://www.aemps.gob.es/.

--------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Mepivacaine B. Braun 20 mg/ml should only be used by doctors with experience in regional anesthesia and resuscitation techniques or under their supervision. Resuscitation equipment should be available when local anesthetics are administered. The lowest possible dose that produces the desired effect should be administered. The dose must be adjusted individually according to the specific particulars of each case.

Dosage

The smallest required dose should always be used to produce the desired anesthesia. The dosage must be adjusted individually according to the patient's age, weight, and specific case particulars.

.

Caudal and epidural anesthesia, peripheral nerve blocks:

The dose should not exceed 400 mg.

The maximum daily dose is 1g.

Mepivacaine B. Braun 20 mg/ml solution for injection can be administered continuously.

For different types of uses, the following doses are recommended:

Sciatic nerve block

15 – 20 ml

Brachial plexus block

3 - 5 ml

Ophthalmic surgery

  • Retrobulbar block

3 ml

  • Peribulbar block (total dose)

5 -7.5 ml

Epidural anesthesia for surgery

5 – 15ml

Caudal anesthesia

10 – 20 ml

For more details on the doses applied for anesthetizing specific nerves or for specific anesthetic techniques, consult standard textbooks.

Elderly Patients

Lower doses may be necessary for elderly patients or those in poor general condition.

Pediatric Population

The doses for adolescents from 15 years of age are those indicated above for adults.

It is not indicated for children under 15 years of age.

Hepatic Insufficiency

In patients with hepatic insufficiency, no dose reduction is necessary for surgical anesthesia.

When prolonged blocks are used, for example, through repeated administration, the repeated doses of mepivacaine should be reduced by 50% in patients with grade C hepatic disease (Child-Pugh classification), and the total dose in 24 hours should not exceed 750 mg of mepivacaine.

Renal Insufficiency

No dose reduction is necessary for surgical anesthesia in patients with renal dysfunction up to 24 hours.

Administration

  • Perineural, epidural route for nerve conduction block.
  • Ophthalmic surgery: administration routes for peri and retrobulbar blocks.

Local anesthesia should not be injected into infected areas.

Before injection, it must be ensured that the needle is not situated intravascularly.The injection should be performed slowly and fractionally.

Basic guidelines to follow:

  1. Choose the lowest possible dosage.
  2. Use a needle of the appropriate dimension.
  3. Inject slowly with several aspirations in two planes (rotate the needle 180º).

Great care must be taken to avoid accidental intravascular injection. It is essential to perform careful aspiration.

  1. Monitor blood pressure.
  2. Take into account premedication. Premedication should include the prophylactic administration of atropine and - depending on the convenient amounts of local anesthetic to be injected - a short-acting barbiturate.
  3. If necessary, suspend the administration of anticoagulants before the administration of the local anesthetic.
  4. Observe the general and specific contraindications for the various methods of local or regional anesthesia.

For continuous epidural administration, more diluted mepivacaine solutions should be used.

For epidural anesthesia, a test dose should be administered, which consists of 3 - 4 ml of a local anesthetic with added adrenaline (1: 200,000) before the complete dose, because an intravascular injection of adrenaline is quickly recognized due to the increase in heart rate. The heart rate should be measured repeatedly until 5 minutes after the administration of the test dose.

Verbal contact with the patient should be maintained and the heart rate should be measured repeatedly until 5 minutes after the administration of the test dose. Aspiration should be repeated before administering the main dose. The main dose should be injected slowly and, especially when increasing the dose, constant contact with the patient should be maintained. Administration should be interrupted immediately at the first symptoms of toxicity.

Before administering a local anesthetic, it must be ensured that the necessary equipment for resuscitation, e.g.: oxygen source, material to keep the respiratory tract clear and emergency medication for the treatment of toxic reactions, is available immediately.

Online doctors for MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION

Discuss questions about MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (5)
Doctor

Anastasiia Hladkykh

Psychiatry 15 years exp.

Dr Anastasiia Hladkykh is a physician-psychotherapist and psychologist with over 14 years of experience working with individuals struggling with various types of addictions and their families. She provides online consultations for adults, combining medical knowledge with deep psychological support and practical tools.

Key areas of expertise:

  • Addiction treatment: alcohol and drug dependence, gambling addiction, compulsive behaviours, codependent relationships.
  • Support for families of addicted individuals, behavioural correction within the family system, guidance for maintaining remission.
  • Mental health: depression, bipolar disorder, obsessive-compulsive disorder (OCD), anxiety disorders, phobias, PTSD, generalised anxiety, emotional trauma, and the psychological impact of loss or emigration.
  • Psychoeducation: explaining complex mental health concepts in simple language, helping patients and their families understand diagnoses and treatment steps.
Therapeutic approach:
  • Client-centred, straightforward, and empathetic – focused on practical outcomes and emotional stabilisation.
  • Prescribes medications when needed, but always aims to minimise unnecessary pharmaceutical use.
  • Certified in multiple evidence-based methods: CBT, NLP (Master Practitioner), Ericksonian hypnosis, symbol drama, art therapy, and systemic therapy.
  • Each consultation results in a clear, structured plan – patients leave knowing exactly what to do next.
Experience and background:
  • Member of the German association Gesundheitpraktikerin and the NGO “Mit dem Sonne in jedem Herzen.”
  • More than 18 publications in international peer-reviewed journals, translated into several languages.
  • Volunteer work with Ukrainian refugees and military personnel at the University Clinic of Regensburg.
Camera Book a video appointment
€130
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION?
MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION?
The active ingredient in MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION is mepivacaine. This information helps identify medicines with the same composition but different brand names.
Who manufactures MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION?
MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION is manufactured by B Braun Medical S.A.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to MEPIVACAINE B. BRAUN 20 mg/mL INJECTABLE SOLUTION?
Other medicines with the same active substance (mepivacaine) include ISOGAINE 30 mg/ml INJECTABLE SOLUTION, MEPIVACAINE B. BRAUN 10 mg/mL INJECTABLE SOLUTION, MEPIVACAINE DERMOGEN 30 mg/ml INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media